|
Days after the start of administration
|
-1
|
3
|
7
|
10
|
14
|
17
|
21
|
28
|
42
|
56
|
|---|
|
Arsenic concentrations (ngAs/g)
|
As(V)
|
0.36
|
0.96
|
0.69
|
0.99
|
1.26
|
1.03
|
1.34
|
1.50
|
0.99
|
0.24
|
| |
As(III)
|
0
|
1.50
|
1.86
|
2.02
|
6.31
|
5.89
|
5.74
|
7.89
|
5.83
|
0.09
|
| |
MA(V)
|
0.55
|
6.91
|
8.30
|
10.46
|
10.59
|
10.24
|
13.99
|
13.50
|
14.05
|
1.87
|
| |
DMA(V)
|
0.11
|
6.14
|
10.3
|
12.2
|
13.2
|
14.0
|
14.0
|
13.3
|
15.3
|
3.96
|
| |
AB
|
0.60
|
1.94
|
1.06
|
1.39
|
0.43
|
1.04
|
0.88
|
3.80
|
0.99
|
1.22
|
- Blood samples were collected before the treatment start (day -1), and 3, 7, 10, 14, 17, 21, 28, 42, 56 days after the start of administration. The concentrations of arsenic species in PB plasma were determined by HPLC/ICP-MS as described in "Patient and Methods".
